HOBOKEN, N.J.--(BUSINESS WIRE)--Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human) 10% (100 mg/mL) Liquid ...
Immune Globulin Intravenous (Octagam (5 gm)) is a blood product administered intravenously, prescribed for primary immunodeficiency. GIV boosts the body's natural response in patients with compromised ...
The approval was based on data from the ProDERM study, which evaluated the efficacy and safety of Octagam 10% in 95 adults with dermatomyositis. The Food and Drug Administration (FDA) has approved ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Product Expected to Be Available for Distribution in a Few Weeks HOBOKEN, N.J. (November 4, 2011) - The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of ...
Octapharma USA today announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam ® 10% [Immune ...
( )--Octapharma announced today the results from the ProDERM study on the efficacy and safety of octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been ...
The Company has decided in conjunction with the FDA to suspend further administration of Octagam 10% from these specific production lots. Octapharma has initiated a voluntary market withdrawal of ...
PARAMUS, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on ...
The FDA approved intravenous immunoglobulins (IVIG; Octagam 10%) for treating adults with dermatomyositis, a rare chronic autoimmune disease, drugmaker Octapharma announced on Tuesday. Support for the ...
The first trial of this IVIG preparation in Alzheimer's evaluated six different doses of Octagam 10 percent against two placebo comparators in a six-month trial of 58 people with mild to moderate AD.
PARAMUS, N.J. (May 20, 2020) - The U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application submitted by Octapharma USA for a phase three clinical trial on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results